retatrutide weight loss clinical trials Trial of next-gen weight-loss drug brings it one step closer to FDA approval If retatrutide isn't FDA approved

Oral semaglutide (Rybelsus) requires special consideration, as it must also be taken on an empty stomach and can increase thyroxine exposure when coadministered with levothyroxine, potentially necessitating dose adjustments and careful TSH monitoring

These peptides are sold strictly as research chemicals and are not intended for human consumption or clinical use

Standard TB-500 protocol: Loading phase (Weeks 1-4): 5mg twice weekly (Monday/Thursday) Total per week: 10mg Total for loading: 40mg (8 vials of 5mg) Maintenance phase (Weeks 5-12): 2-5mg once weekly Total per week: 2-5mg Total for maintenance: 16-40mg (3-8 vials) Example: 5mg vial + 2ml water = 2,500mcg/ml 5mg dose (5,000mcg) = draw 2.0ml (full vial) 2.5mg dose = draw 1.0ml TB-500 doses are MUCH larger than BPC-157

Decreased SIRT1 expression in colon epithelial cells of UC patients and DSS-induced mice correlates with immune dysregulation (Caruso et al., 2014